Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Osmach 100micrograms/hour transdermal patches
0407020A0BHADAH
|
Osmach | Fentanyl | Central Nervous System | No data available |
|
Osmach 25micrograms/hour transdermal patches
0407020A0BHAAAE
|
Osmach | Fentanyl | Central Nervous System | No data available |
|
Osmach 50micrograms/hour transdermal patches
0407020A0BHABAF
|
Osmach | Fentanyl | Central Nervous System | No data available |
|
Osmach 75micrograms/hour transdermal patches
0407020A0BHACAG
|
Osmach | Fentanyl | Central Nervous System | No data available |
|
Osmanil 100micrograms/hour transdermal patches
0407020A0BLADAH
|
Osmanil | Fentanyl | Central Nervous System | No data available |
|
Osmanil 12micrograms/hour transdermal patches
0407020A0BLAEAU
|
Osmanil | Fentanyl | Central Nervous System | No data available |
|
Osmanil 25micrograms/hour transdermal patches
0407020A0BLAAAE
|
Osmanil | Fentanyl | Central Nervous System | No data available |
|
Osmanil 50micrograms/hour transdermal patches
0407020A0BLABAF
|
Osmanil | Fentanyl | Central Nervous System | No data available |
|
Osmanil 75micrograms/hour transdermal patches
0407020A0BLACAG
|
Osmanil | Fentanyl | Central Nervous System | No data available |
|
Ospolot 200mg tablets
0408010Y0BBABAB
|
Ospolot | Sultiame | Central Nervous System | No data available |
|
Ospolot 20mg/ml oral suspension
0408010Y0BBACAE
|
Ospolot | Sultiame | Central Nervous System | No data available |
|
Otricaps Blocked Nose and Sinusitis Relief capsules
0407010X0DHAAAF
|
Otricaps | Paracetamol combined preparations | Central Nervous System | No data available |
|
Oxazepam 12.5mg/5ml oral suspension
0401020T0AAAIAI
|
Oxazepam | Oxazepam | Central Nervous System | No data available |
|
Oxazepam 2.5mg/5ml oral suspension
0401020T0AAAHAH
|
Oxazepam | Oxazepam | Central Nervous System | No data available |
|
Oxazepam 2mg/5ml oral suspension
0401020T0AAAKAK
|
Oxazepam | Oxazepam | Central Nervous System | No data available |
|
Oxcarbazepine 400mg/5ml oral suspension
0408010D0AAAFAF
|
Oxcarbazepine | Oxcarbazepine | Central Nervous System | No data available |
|
Oxitriptan 50mg capsules
0403040R0AAAFAF
|
Oxitriptan | Oxitriptan | Central Nervous System | No data available |
|
Oxitriptan 50mg modified-release tablets
0403040R0AAAKAK
|
Oxitriptan | Oxitriptan | Central Nervous System | No data available |
|
Oxyargin 10mg/5mg modified-release tablets
0407020AFBDABAA
|
Oxyargin | Oxycodone hydrochloride/naloxone hydrochloride | Central Nervous System | No data available |
|
Oxyargin 20mg/10mg modified-release tablets
0407020AFBDACAB
|
Oxyargin | Oxycodone hydrochloride/naloxone hydrochloride | Central Nervous System | No data available |
|
Oxycodone 30mg suppositories
0407020Z0AAAAAA
|
Oxycodone | Oxycodone | Central Nervous System | No data available |
|
Oxycodone 40mg/5ml / Naloxone 20mg/5ml oral suspension
0407020AFAAAEAE
|
Oxycodone hydrochloride/naloxone hydrochloride | Oxycodone hydrochloride/naloxone hydrochloride | Central Nervous System | No data available |
|
Oxycodone hydrochloride 60mg suppositories
0407020Z0AAABAB
|
Oxycodone | Oxycodone | Central Nervous System | No data available |
|
Oxylan 10mg modified-release tablets (Actavis)
0407020ADBFAGAF
|
Oxylan | Oxycodone hydrochloride | Central Nervous System | No data available |
|
Oxylan 20mg modified-release tablets (Actavis)
0407020ADBFAHAG
|
Oxylan | Oxycodone hydrochloride | Central Nervous System | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.